Valuation : Cell Source, Inc.

Market Cap 24.41M 21.03M 19.91M 18.05M 33.86M 2.33B 34.04M 237M 90.95M 1.19B 91.68M 89.66M 3.75B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 30.09M 28.49M 25.82M 48.44M 3.34B 48.69M 338M 130M 1.7B 131M 128M 5.36B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+15.56%
1 week+0.56%
Current month-41.57%
1 month-36.84%
3 months-32.47%
6 months-46.93%
Current year+4.00%
1 week 0.45
Extreme 0.45
0.68
1 month 0.45
Extreme 0.45
0.89
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 29/06/2014
Director TitleAgeSince
Chairman 77 17/05/2015
Director/Board Member 82 24/03/2021
Director/Board Member 72 09/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
09/08/21 Others

Director

800,000 2.4492%
30/06/21 Others

Director

4,860 0.0149%
30/06/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+15.56%+0.56%+10.64%+19,159.26% 30.58M
-2.11%-1.68%+44.52%+95.15% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+1.67%+2.47%-11.23%+388.34% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
+0.34%-6.78%-7.27%-17.99% 24.22B
+0.43%-3.37%+14.85%-19.29% 19.36B
-3.03%-2.29%+185.12%+334.07% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-2.28%-4.90%+43.64%+155.21% 14.23B
Average +0.74%-3.33%+33.59%+2,067.41% 27.27B
Weighted average by Cap. -0.86%-3.30%+33.85%+135.85%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.58M -4.34M -3.93M -7.38M -508M -7.42M -51.56M -19.83M -259M -19.98M -19.55M -817M -4.51M -3.89M -3.68M -3.34M -6.26M -431M -6.29M -43.72M -16.81M -219M -16.95M -16.58M -693M
Net Debt 9.27M 7.99M 7.57M 6.86M 12.87M 886M 12.93M 89.86M 34.55M 451M 34.83M 34.07M 1.42B 10.51M 9.05M 8.57M 7.77M 14.58M 1B 14.65M 102M 39.15M 511M 39.46M 38.6M 1.61B
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
11/09/26 US$0.5200 +15.56% 12,750
10/09/26 US$0.4500 -10.00% 9,470
09/09/26 US$0.5000 -26.47% 12,140
08/09/26 US$0.6800 +31.50% 1,200
04/09/26 US$0.5171 -29.81% 5,000
  1. Stock Market
  2. Stocks
  3. CLCS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!